Technology & Science
How does liquid biopsy compare with tissue biopsy in terms of accuracy and reliability?
What are the main biomarkers used in liquid biopsy—circulating tumor DNA (ctDNA), exosomes, or circulating tumor cells?
Can AI-driven analysis make liquid biopsy results more precise and faster?
🔹 Clinical Applications
Is liquid biopsy ready to replace traditional biopsies, or should it remain a complementary tool?
How effective is liquid biopsy in early cancer detection versus disease monitoring?
Beyond oncology, what other areas (like prenatal testing, organ transplant rejection, infectious diseases) could benefit from liquid biopsy?
🔹 Market & Business
With the market for liquid biopsy expanding rapidly, which sectors (oncology, pharma, diagnostics) stand to benefit most?
How can startups compete with established diagnostic giants in this space?
Will falling costs make liquid biopsy tests widely accessible, or will they remain limited to premium healthcare systems?
🔹 Ethical & Policy
Should patients have the right to direct access to their liquid biopsy results, or should interpretation always go through physicians?
How can regulators ensure test validity and standardization across providers?
Could insurers push for mandatory liquid biopsy screenings in certain high-risk groups?
🔹 Future Outlook
Will liquid biopsy become the standard first-line cancer diagnostic in the next decade?
Could real-time, at-home liquid biopsy devices ever be a reality?
How might liquid biopsy reshape personalized medicine and targeted therapies?
